Print

High-Speed Expendable Aerial Target ‘ABHYAS’ completes developmental trials with improved booster configuration

DRDO has successfully completed six consecutive developmental trials of High Speed Expendable Aerial Target (HEAT) ‘ABHYAS’ with improved booster configuration from the integrated test range (ITR), Chandipur in Odisha.

With this, ABHYAS has successfully completed 10 developmental trials, demonstrating the reliability of the system.
The developmental trials were carried out with improved Radar Cross Section (RCS), Visual and IR augmentation systems.
During the flight trial, various mission objectives covering safe release of boosters, launcher clearance, and endurance performance were successfully validated.

Two launches were conducted back-to-back within a gap of thirty minutes, demonstrating the ease of operation with minimal logistics. Representatives from Services witnessed the flight trials.

ABHYAS has been designed by DRDO’s Aeronautical Development Establishment (ADE), Bengaluru, and developed through Production Agencies M/s HAL & M/s L&T. It offers a realistic threat scenario for weapon systems practice.

This indigenous system is designed for autonomous flying with the help of an autopilot and a laptop-based Ground Control System (GCS) for aircraft integration, pre-flight checks, and autonomous flight.

It also has a feature to record data during flight for post-flight analysis. The booster has been designed by Advanced Systems Laboratory (ASL) and the navigation system by Research Centre Imarat (RCI). With identified production agencies, ABHYAS is now ready for production.

Defence Minister Rajnath Singh complimented DRDO, the Armed Forces and industry for the developmental trials of the High-speed Expendable Aerial Target (HEAT) – ‘ABHYAS’ and said that the successful tests are noteworthy testimony of synergy between scientists and industry.

Secretary, Department of Defence R&D and Chairman DRDO congratulated the teams associated with successful flight trial of ‘ABHYAS’ and said that the system is cost effective with huge export potential.

(ANI)

RELATED ARTICLES

3 mins ago | Biocon gets European Commission nod

Biocon gets European Commission nod for breast cancer biosimilar Pebrilzo

Biopharmaceutical firm Biocon Ltd has received marketing authorisation from the European Commission (EC) for Pebrilzo, its pertuzumab biosimilar, to treat HER2-positive breast cancer across multiple disease stages in the European Union. Biocon's per...

13 mins ago | Crimean Bridge

Ukraine cripples Crimean road bridge in blow to Putin before meeting with Xi and Trump

Ukrainian drones and missiles destroyed the central road section of the bridge linking Russia and Crimea on Tuesday, inflicting a military and symbolic blow on President Vladimir Putin two days before he is due to meet the leaders of China and the US...

18 mins ago | Iranian attacks

Bahrain, Kuwait report Iranian attacks; US strikes Iranian missile site on Qeshm Island

Kuwait and Bahrain reported fresh Iranian attacks on Wednesday, amid renewed escalation in hostilities between the USA and Iran starting last week. Kuwait's Army posted on social media around midnight that their air defences were responding to hostil...